Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on PPL, Lowers Price Target to $32

Morgan Stanley analyst Stephen Byrd maintains PPL (NYSE:PPL) with a Equal-Weight and lowers the price target from $33 to $32.

byBenzinga Newsdesk

July 20, 2021

1 minute read

Morgan Stanley analyst Stephen Byrd maintains PPL (NYSE:PPL) with a Equal-Weight and lowers the price target from $33 to $32.

Raymond James Upgrades CubeSmart to Market Perform

By Benzinga Newsdesk

Today, 10:21 PM

Raymond James analyst Jonathan Hughes upgrades CubeSmart (NYSE:CUBE) from Underperform to Market Perform.

CUBE

Truist Securities Maintains Buy on UiPath, Lowers Price Target to $45

By Benzinga Newsdesk

Today, 10:21 PM

Truist Securities analyst Terry Tillman maintains UiPath (NYSE:PATH) with a Buy and lowers the price target from $55 to $45.

PATH

Predictive Oncology Q3 EPS $(0.08) Up From $(0.46) YoY, Sales $313.66K Down From $480.76K YoY

By Benzinga Newsdesk

Today, 10:21 PM

Predictive Oncology (NASDAQ:POAI) reported quarterly losses of $(0.08) per share. This is a 82.61 percent increase over losses of $(0.46) per share from the same period last year. The company reported $313.66 thousand

POAI

FDA
News

Dicerna Reports Top-Line REsults From PHYOX 2 Trial Of Nedosiran For Treatment Of Primary Hyperoxaluria Met Primary Endpoint

By Benzinga Newsdesk

Today, 10:21 PM

– Nedosiran Achieved Primary Endpoint, Demonstrating Statistically and Clinically Significant Sustained Reduction in Urinary Oxalate Excretion; Key Secondary Endpoint Also Achieved; Robust Efficacy Seen in PH1

DRNA

Morgan Stanley Maintains Equal-Weight on PPL, Lowers Price Target to $32

Related Posts

Raymond James Upgrades CubeSmart to Market Perform

Truist Securities Maintains Buy on UiPath, Lowers Price Target to $45

Predictive Oncology Q3 EPS $(0.08) Up From $(0.46) YoY, Sales $313.66K Down From $480.76K YoY

Dicerna Reports Top-Line REsults From PHYOX 2 Trial Of Nedosiran For Treatment Of Primary Hyperoxaluria Met Primary Endpoint